Fosamax (alendronate) is now approved for treating osteoporosis in men or women taking chronic glucocorticoids
August 1999
Fosamax (alendronate) is now approved for treating osteoporosis in men or women taking chronic glucocorticoids.
This new indication is for patients who take the equivalent of 7.5 mg/day or more of prednisone...AND have low bone mineral density.
These patients can lose up to 15% of their overall bone mass in their first year on steroids. Fractures occur in up to 50% of people on long-term steroids.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote